5 Things You Need to Know About COVID, Flu and RSV Vaccines This Fall
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
BioAge Appoints Former GSK CEO Jean-Pierre Garnier as Chair of Its Board of Directors
GlaxoSmithKline (GSK.US) initiates a Phase 2 single-arm clinical study of Dotatilimab in China.
The official website of the China Drug Clinical Trial Registration and Information Disclosure Platform recently announced that GlaxoSmithKline (GSK) has initiated a phase 2 single-arm clinical study of dostarlimab in China, aiming to conduct the study in untreated dMMR/MSI-H locally advanced rectal cancer patients in China.
Express News | The FDA Has Granted Breakthrough Therapy Designation To GSK's GSK5764227, An Investigational B7-H3-Targeted Antibody-drug Conjugate Being Evaluated For Extensive-stage Small-cell Lung Cancer With Disease Progression On Or After Platinum-based...
GSK's Lung Cancer Drug Fast-Tracked by FDA
